Senescent cells are damaged cells that stop dividing but remain metabolically active, secreting pro-inflammatory molecules. Evidence suggests they contribute to ageing-related diseases, and their removal has shown promise in animal models, though human data is still emerging.
Senescent cells are cells that have permanently exited the cell cycle due to stress or damage, but instead of dying, they persist and secrete a complex mix of pro-inflammatory and tissue-remodelling molecules known as the Senescence-Associated Secretory Phenotype (SASP). This phenomenon is increasingly recognised as a significant contributor to the biological processes of ageing and numerous age-related diseases.
The concept of cellular senescence, first described by Hayflick and Moorhead in 1961, has evolved from an in vitro observation to a fundamental mechanism in vivo. Research in animal models, particularly mice, provides compelling evidence that senescent cells accumulate with age and contribute to various pathologies. For instance, selective removal of senescent cells in progeroid and naturally aged mice has been shown to prevent or alleviate multiple age-related conditions, including frailty, cardiovascular dysfunction, kidney disease, and neurodegeneration (Baker et al., Nature, 2016; Xu et al., Nat Med, 2018). These studies often utilise genetically engineered mice where senescent cells can be induced to undergo apoptosis, demonstrating a causal link between senescent cell burden and age-related decline. While human studies are more challenging, senescent cells have been identified in human tissues associated with age-related diseases, such as atherosclerotic plaques, osteoarthritic joints, and fibrotic organs (Kirkland et al., J Am Geriatr Soc, 2017). The presence of the SASP components has also been detected in human plasma and tissues, correlating with markers of inflammation and ageing (Jurk et al., Nat Rev Mol Cell Biol, 2014).
“Accumulation of senescent cells drives age-related pathologies, and their targeted removal can delay, prevent, or alleviate these conditions in mice.”
— van Deursen, Nature 2014
Harvard Health generally provides a sound overview, correctly identifying senescent cells as 'zombie cells' that stop dividing but refuse to die, and that they contribute to chronic inflammation and tissue damage. They accurately highlight that senescent cells accumulate with age and in areas of injury or disease, and that the SASP is a key mechanism through which these cells exert their detrimental effects. The article also correctly points out that research into senolytics – compounds that selectively eliminate senescent cells – is a promising area for future therapeutic interventions. They often cite the compelling animal data that underpins much of the excitement in the field, acknowledging the potential for these findings to translate to human health.
While Harvard Health accurately describes the general concept, some presentations can sometimes oversimplify the complexity. For example, the precise role of senescent cells can be context-dependent; some studies suggest that acute, transient senescence can be beneficial in wound healing and tumour suppression (Demaria et al., Cancer Discov, 2014). The distinction between beneficial and detrimental senescence is often not fully explored. Furthermore, while animal data is robust, the direct causal evidence in humans for senescent cell accumulation driving specific diseases remains largely inferential. Human clinical trials for senolytics are still in their early stages, and the long-term safety and efficacy are yet to be established. Claims about specific natural compounds being 'proven' senolytics in humans are often premature, relying heavily on preclinical data (Tier III) or small, unblinded human studies (Tier II).
For individuals seeking to optimise their healthspan, the current understanding of senescent cells reinforces the importance of lifestyle factors that minimise cellular damage and inflammation. These include maintaining a healthy diet rich in antioxidants, regular physical activity, managing stress, and avoiding environmental toxins. While senolytic drugs are under investigation, there are currently no clinically approved and widely recommended interventions for senescent cell removal in healthy individuals. Some natural compounds, such as quercetin and fisetin, have shown senolytic activity in preclinical models, but their efficacy and safety for this purpose in humans are not yet established. Therefore, focusing on broad health-promoting behaviours remains the most evidence-based approach.
Vitaei verdict
The concept that senescent cells contribute to ageing and disease is strongly supported by animal evidence, but direct causal human evidence and therapeutic applications are still emerging and require further robust investigation.